Sign In
Buy RVMD
$155.99
+4.68 (+3.09%)
At Close: Jun 03, 2026
Piper starts Revolution Medicines at Overweight on daraxonrasib potential
06:28am, Tuesday, 19'th Aug 2025
Piper Sandler analyst Kelsey Goodwin last night initiated coverage of Revolution Medicines with an Overweight rating and $75 price target. The firm believes the stock's value will be driven by confide
Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript
05:49am, Thursday, 07'th Aug 2025
Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Anthony Mancini - Chief Global Commercialization Officer Jack Anders - Chief F
Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress
04:02pm, Wednesday, 06'th Aug 2025
REDWOOD CITY, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
04:05pm, Wednesday, 30'th Jul 2025
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
10:55am, Monday, 28'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionabl
REDWOOD CITY, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib
08:00am, Wednesday, 23'rd Jul 2025
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior che
Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near
REDWOOD CITY, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted
REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
07:19am, Tuesday, 24'th Jun 2025
Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonras
REDWOOD CITY, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
REDWOOD CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted c
Revolution Medicines: Positioning Itself To Capture One Of The Largest Cancer Targets In History
11:54am, Thursday, 19'th Jun 2025
Revolution Medicines is advancing a groundbreaking pan-RAS inhibitor pipeline, targeting historically undruggable mutations in tough cancers like pancreatic and lung. Early clinical data for daraxonra
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ca
